Immunotherapy

December 2020 Vol 11, No 12 | December 4, 2020
The authors provide a brief background and an overview of cancer vaccine therapy, current research, clinical application, and current challenges.
October 2020 Vol 11, No 10 | October 6, 2020
For some patients, the use of CAR-T cell therapy has resulted in robust and durable (>95%) responses lasting longer than 5 years. Here’s what you need to know about CAR T-cell therapy.
September 2020 Vol 11, No 9 | September 9, 2020
Historically, surgery, chemotherapy, and radiation have been the mainstay of most cancer therapies. Although these modalities have been successful and improved survival outcomes, cancer remains one of the most debilitating diagnoses, often with poor outcomes.
Web Exclusives | December 3, 2019
The FDA has granted priority review to Merck’s supplemental Biologics License Application for the anti-PD–1 agent pembrolizumab as monotherapy for certain patients with high-risk, non-muscle invasive bladder cancer who are ineligible for or have elected not to undergo cystectomy.
January 2019 Vol 10, No 1 | January 11, 2019
Carsten Kampe, MD, PhD, discusses the excitement surrounding immunotherapy at the AONN+ Annual Conference
Immunotherapy drugs work by boosting the immune system so that a person’s own immune system works smarter to identify and destroy any cancer cells.
Page 1 of 3
Results 1 - 10 of 28

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code